Press release
Investigation announced for Long-Term Investors in shares of Centessa Pharmaceuticals plc (NASDAQ: CNTA)
An investigation on behalf of investors in Centessa Pharmaceuticals plc (NASDAQ: CNTA) shares.
Investors who are current long term investors in Centessa Pharmaceuticals plc (NASDAQ: CNTA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: CNTA stocks follows a lawsuit filed against Centessa Pharmaceuticals plc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: CNTA stocks, concerns whether certain Centessa Pharmaceuticals plc directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Central District of California the plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that lixivaptan was less safe than Defendants had represented, that Defendants overstated lixivaptan's clinical and commercial prospects, that ZF874 was less safe than Defendants had represented; (iv) Defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues, and that as a result, the Offering Documents and the Company's public statements between May 28, 2021 and June 1, 2022were materially false and/or misleading and failed to state information required to be stated therein.
Those who purchased shares of Centessa Pharmaceuticals plc (NASDAQ: CNTA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Centessa Pharmaceuticals plc (NASDAQ: CNTA) here
News-ID: 2925763 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Centessa
Hemophilia Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatm …
DelveInsight's, "Hemophilia- Pipeline Insight, 2025," report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Hemophilia Pipeline constitutes 80+ key companies continuously working towards developing 80+ Hemophilia treatment…
Hypersomnia Clinical Trials, Drugs, Companies, Hypersomnia Treatment Market, 202 …
Hypersomnia Pipeline constitutes 3+ key companies continuously working towards developing 4+ Hypersomnia treatment therapies, analyzes DelveInsight.
Hypersomnia Overview:
Hypersomnia is a disorder marked by excessive daytime sleepiness, which can greatly disrupt daily activities, productivity, and overall quality of life. It often results in sudden, unplanned episodes of sleep or drowsiness, known as sleep attacks, without obvious signs of tiredness beforehand. As a significant public health issue, hypersomnia is linked to increased risks…
Pulmonary Hypertension Market to Grow at a Substantial Growth Rate During the Fo …
The Pulmonary Hypertension market size is expected to grow in the coming years owing to the increasing prevalence and expected launch of pipeline products in the market. Multiple new drugs are going through different phases of clinical trials; these upcoming therapies are expected to be a better treatment option for Pulmonary Hypertension in the coming years.
DelveInsight's " [https://www.delveinsight.com/report-store/pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology,…
Deadline on November 28th coming up in Lawsuit for Investors in Centessa Pharmac …
A deadline is coming up on November 28, 2022 in the lawsuit filed for certain investors of Centessa Pharmaceuticals plc (NASDAQ: CNTA).
Investors who purchased shares of Centessa Pharmaceuticals plc (NASDAQ: CNTA) have certain options and there are strict and short deadlines running. Deadline: November 28, 2022. NASDAQ: CNTA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District…
Lawsuit filed for Investors in shares of Centessa Pharmaceuticals plc (NASDAQ: C …
An investor, who purchased shares of Centessa Pharmaceuticals plc (NASDAQ: CNTA), filed a lawsuit over alleged Securities Laws violations by Centessa Pharmaceuticals plc in connection with certain allegedly false and misleading statements made in connection with the Company's initial public offering conducted on or about May 28, 2021 (the "IPO" or "Offering") and between May 28, 2021 and June 1, 2022.
Investors who purchased shares of Centessa Pharmaceuticals plc (NASDAQ:…
Investigation announced for Investors in Centessa Pharmaceuticals plc (NASDAQ: C …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Centessa Pharmaceuticals plc.
Investors who purchased shares of Centessa Pharmaceuticals plc (NASDAQ: CNTA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Centessa Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
United Kingdom…
